Kidney Week

Why Submit to Kidney Week?

• Reach a global audience: Approximately 12,000 leading nephrologists, researchers, industry professionals, and others attend this largest kidney meeting in the world.
• Gain immediate recognition: Attract media attention and scientific interest. All main stage podium presentations will be invited to present at a press-embargoed session.

What's New?

• Featured high-impact clinical trials in the Opening Plenary.
• More presentation time for high-impact research.
• Multiple late-breaking oral sessions.

Eligibility

Your late-breaking clinical trial (LBCT) submission MUST meet the following criteria for ASN consideration:

• ASN gives preference to Phase 2, 3, and 4 trials. We welcome positive or negative outcomes. We welcome secondary data analysis of previously presented RCTs, offering new insights and interpretations.
• Your data has not been and will not be presented at a United States or international meeting before presentation at Kidney Week.
• Your data has not been and will not be published in any form (including preprint servers) before presentation at Kidney Week.
• ASN has adopted the ICMJE criteria: "authorship be based on...1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or reviewing it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved." For your LBCT submission:
  • ALL authors must be added to the abstract at the time of submission.
  • ALL authors must have full access to all study data and statistical analyses of the data. If that is not the case, the abstract may be rejected or retracted.
  • Based on the above ICMJE criteria for authorship, artificial intelligence (AI) tools, such as ChatGPT, do not qualify for authorship.
• The Submitter has the authority to submit the LBCT and transfer copyright on behalf of the co-authors and company sponsors
• All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
• If AI tools, such as ChatGPT "are used to create content or assist with writing or manuscript preparation, authors must take responsibility for the integrity of the content generated by these tools. Authors should report the use of artificial intelligence, language models, machine learning, or similar technologies to create content or assist with writing or editing of manuscripts in the Methods section if this is part of formal research design or methods. This should include a description of the content that was created or edited and the name of the language model or tool, version and extension numbers, and manufacturer. (Note: this does not include basic tools for checking grammar, spelling, references, etc.)" [JAMA Network Authorship Criteria and Contributions]
• "The submission and publication of images created by artificial intelligence, machine learning tools, or similar technologies is discouraged, unless part of formal research design or methods, and is not permitted without clear description of the content that was created and the name of the model or tool, version and extension numbers, and manufacturer. Authors must take responsibility for the integrity of the content generated by these models and tools." [JAMA Network Statistical Methods and Data Presentation]

Important

• Submit as much data as possible. If results are not available at the time of submission, please include the expected date available.
• Do not submit multiple abstracts on the same trial – only one abstract submission per trial.

Submission Details

1. All LBCT abstracts must be submitted electronically through the ASN abstract submission site by September 9, 2025, 2:00 p.m. EDT for consideration.
2. 2. ALL authors (including co-authors) must create an ASN User Login, if they do not already have one, BEFORE they can be added to an abstract. Please tell your authors to complete this step as soon as possible.
   • Submitter/Submitting Author: This individual serves as the secondary point of contact with ASN regarding the submission. The Submitter is not required to be a contributing author (e.g., administrative assistant or student working with the authors) but must have an ASN User Login with current contact information for submission.
   • Presenting (First) Author: This individual is the first author listed in the submission and has the primary responsibility for communications with ASN. The Presenting Author is responsible for ensuring that ALL co-authors approve the submission, publication, and potential presentation. The Presenting Author is responsible for ensuring that ALL co-authors who participated in the study and meet the criteria for authorship are listed on the abstract when it is submitted to ASN. The Presenting Author will give the oral or poster presentation, if the submission is accepted, and should feel comfortable presenting and answering questions in English. Please note that the submission system recognizes the first author as the Presenting Author; these roles cannot be differentiated in the system or in the Kidney Week program. The Presenting Author must be the first author listed.
   • Co-Authors: The co-authors will be listed in the order provided during submission.
3. An abstract submission may contain a maximum of 2,500 characters. The total character count includes characters and spaces in the following fields: Title, Body, Figures (up to 2), Table (up to 1), Author Names (as they appear once added on Step 4 of the submission process). Figure count is determined by image height but will not exceed 560 characters. Because image height cannot be calculated manually, we recommend uploading, editing, and replacing figures in the submission until an acceptable quality : character ratio is reached. Table count is 50 characters per row. For complex tables and in situations where control over formatting is desired, we recommend uploading the table as a figure. Author Institutions do not count towards the character count.
4. The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An abstract may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee by September 9, 2025, at 2:00 p.m. EDT.
5. There is no limit to the number of abstracts that an individual may submit. However, there is a $95 nonrefundable processing fee per submission. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
6. Upon abstract submission, ALL authors agree to all copyright transfer terms and the ASN embargo policy.
7. Changes: It is important that the lead author checks the abstract data carefully before submission. For submitted abstracts needing changes through September 9, 2025, at 2:00 p.m. EDT, the Submitter can make changes directly in the abstract submission site. After September 9, for submissions needing MINIMAL changes, the Submitter or Presenting (First) Author can email kidneyweek@asn-online.org with the abstract number in the subject line and the ASN Abstract Change Form attached. Change requests will be handled on a case-by-case basis; ASN may not be able to accommodate all requests. Minimal changes include author additions (if the total character limit permits) and typos, but NOT replacement of text, table, and figures.
8. Withdrawals: The lead author can request abstract withdrawal through October 9, 2025, by emailing kidneyweek@asn-online.org. Please note the abstract number in the email subject line and the lead author's name in the email body. The $95 processing fee is nonrefundable. After October 9, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.

Assignment, Notification, and Presentation

All abstract submissions are peer reviewed by the LBCT review committee, and authors' names and institutions are blinded during the review process. LBCT submissions can be (1) accepted as an oral abstract, (2) accepted as a poster, or (3) rejected. There is no publication-only option for LBCT submissions.

Accepted abstracts will be assigned to one of the following:

• NEW! Opening Plenary: Two high-impact clinical trials may be featured in the Opening Plenary on Thursday, November 6, 8:00-9:30 a.m. CST.
• High-Impact Clinical Trials Oral Sessions: These sessions will be held in the plenary room on Friday, November 7, 10:30 a.m. - 12:30 p.m. CST and on Saturday, November 8, 10:30 a.m. - 12:30 p.m. CST. The sessions will be recorded for later viewing.
• Late-Breaking Research Oral Session(s): To be determined.
• Late-Breaking Posters: Posters will be presented in-person in Houston, TX, in the exhibit hall on Thursday, November 6, 10:00 a.m. - 12:00 p.m. CST. If accepted for poster presentation, the Presenting (First) Author or a co-author must be available at the poster board at 10:00 a.m. - 12:00 p.m. CST for presentation and discussion. Poster presenters are encouraged to submit an ePoster to complement their printed poster. ePosters will be available for viewing online starting Thursday, November 6, 10:00 a.m. CST.

Accepted abstracts will be included in the ASN abstract search tool and on the JASN website.

ASN will email notifications to the Presenting (First) Authors and Submitters of all LBCT submissions by 11:59 p.m. EDT on September 30, 2025.

It is the responsibility of the Presenting (First) Author to share the notifications with their co-authors. If you are the Presenting Author and have not received your notification by October 1, please email kidneyweek@asn-online.org and note the abstract number in the email subject line and the Presenting Author's name in the email body.

The Presenting Authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and travel to Houston, TX, to present in-person.

ASN reserves the right to withdraw any submission for any reason in its discretion.

Confidential Advanced Access

All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.

Simultaneous Publication

Simultaneous publication of late-breaking clinical trials is acceptable and encouraged as long as the embargo policies of ASN and the involved journals are coordinated. If a clinical trial has been submitted to and accepted for publication, the Presenting (First) Author is responsible for ensuring that the journal editorial team respects the ASN embargo policy. Publication of a clinical trial either in print or on a journal website prior to presentation at ASN Kidney Week violates the ASN embargo policy. If you are interested in simultaneous publication, please notify the journal editorial team who should then contact ASN Press Officer Christine Feheley at cfeheley@asn-online.org to verify embargo dates/times.